medroxyprogesterone acetate has been researched along with African Lymphoma in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Banda, K; Bunce, CM; Drayson, MT; Dunn, JA; Iqbal, G; Khanim, FL; Merrick, B; Molyneux, E | 1 |
Bunce, CM; Desmond, JC; Drayson, MT; Fenton, SL; Gordon, J; Luong, QT; Mustard, KJ; Pound, J; Sarafeim, A | 1 |
1 trial(s) available for medroxyprogesterone acetate and African Lymphoma
Article | Year |
---|---|
Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi; an open-label, single-arm, phase 2 study (ISRCTN34303497).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bezafibrate; Burkitt Lymphoma; Child; Child, Preschool; Drug Resistance, Neoplasm; Endemic Diseases; Female; Humans; Malawi; Male; Medroxyprogesterone Acetate; Recurrence | 2014 |
1 other study(ies) available for medroxyprogesterone acetate and African Lymphoma
Article | Year |
---|---|
Fibrates and medroxyprogesterone acetate induce apoptosis of primary Burkitt's lymphoma cells and cell lines: potential for applying old drugs to a new disease.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; bcl-X Protein; Burkitt Lymphoma; Cell Division; Clofibric Acid; Drug Interactions; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Medroxyprogesterone Acetate; Proto-Oncogene Proteins c-bcl-2; Transduction, Genetic; Tumor Cells, Cultured | 2003 |